Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.04 USD
+0.11 (5.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -237.89 | -291.75 | -287.10 | 132.24 | 89.83 |
Depreciation/Amortization & Depletion | 3.79 | 3.70 | 3.45 | 2.89 | 3.26 |
Net Change from Assets/Liabilities | -34.35 | -79.26 | 44.57 | -30.40 | -112.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 93.57 | 126.19 | 201.65 | 49.41 | 47.40 |
Net Cash From Operating Activities | -174.88 | -241.12 | -37.43 | 154.15 | 28.36 |
Property & Equipment | -0.29 | -2.04 | -1.29 | -7.23 | -1.82 |
Acquisition/ Disposition of Subsidiaries | 7.84 | 0.00 | 0.00 | 0.18 | 0.00 |
Investments | 138.14 | -127.38 | -1.12 | 0.15 | 0.16 |
Other Investing Activities | -1.05 | -37.43 | -136.00 | -7.50 | -11.08 |
Net Cash from Investing Activities | 144.64 | -166.85 | -138.41 | -14.40 | -12.73 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 74.22 | 9.37 | 54.30 | 17.43 | 5.56 |
Issuance (Repayment) of Debt | 0.00 | 49.93 | -0.67 | 203.60 | 72.96 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -4.62 | -4.97 | -1.75 | 2.92 | 10.86 |
Net Cash from Financing Activities | 69.60 | 54.33 | 51.88 | 223.95 | 89.37 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | -0.28 |
Net Change In Cash & Equivalents | 39.36 | -353.65 | -123.96 | 363.69 | 104.72 |
Cash at Beginning of Period | 63.99 | 417.64 | 541.60 | 177.91 | 73.19 |
Cash at End of Period | 103.34 | 63.99 | 417.64 | 541.60 | 177.91 |
Diluted Net EPS | -2.53 | -3.76 | -3.81 | 1.62 | 1.23 |
Fiscal Year End for Coherus BioSciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -237.89 | -158.24 | -118.60 | -75.73 |
Depreciation/Amortization & Depletion | NA | 3.79 | 2.73 | 1.83 | 0.95 |
Net Change from Assets/Liabilities | NA | -34.35 | -41.18 | -14.30 | -9.35 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 93.57 | 34.74 | 23.42 | 15.39 |
Net Cash From Operating Activities | NA | -174.88 | -161.95 | -107.65 | -68.73 |
Property & Equipment | NA | -0.29 | -0.25 | -0.25 | -0.15 |
Acquisition/ Disposition of Subsidiaries | NA | 7.84 | 7.77 | 0.62 | 0.18 |
Investments | NA | 138.14 | 101.92 | 58.53 | 17.50 |
Other Investing Activities | NA | -1.05 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 144.64 | 109.44 | 58.89 | 17.53 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 74.22 | 73.33 | 61.84 | 6.94 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -4.62 | -4.10 | -3.71 | -3.13 |
Net Cash from Financing Activities | NA | 69.60 | 69.23 | 58.13 | 3.80 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 39.36 | 16.72 | 9.37 | -47.40 |
Cash at Beginning of Period | NA | 63.99 | 63.99 | 63.99 | 63.99 |
Cash at End of Period | NA | 103.34 | 80.71 | 73.36 | 16.59 |
Diluted Net EPS | NA | -0.67 | -0.41 | -0.49 | -0.96 |